Lessons learned from HIV vaccine clinical efficacy trials

Current HIV Research

Volumn 11, Issue 6, 2013, Pages 441-449

  Day, Tracey A ^a   Kublin, James G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Efficacy trial; HIV; HIV vaccine trials network; HVTN; HVTN 505; RV144; Step study; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; GLYCOPROTEIN GP 120; IBALIZUMAB; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE;

ANTIBODY RESPONSE; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; VIRUS ATTENUATION;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; RESEARCH DESIGN;

EID: 84894037174     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162x113116660051     Document Type: Review

References (94)

1. Abdool KQ, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-74.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-99.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6): 493-505.
4. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012; 63: 95-111.
5. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482(7383): 89-93.
6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20.
7. Stover J, Bollinger L, Hecht R, Williams C, Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff (Millwood) 2007; 26(4): 1147-58.
8. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191(5): 654-65.
9. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand. J Infect Dis 2006; 194(12): 1661-71.
10. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191(5): 666-77.
11. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178(10): 6596- 603.
12. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6(2): 207-10.
13. Shibata R, Igarashi T, Haigwood N, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5(2): 204-10.
14. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449(7158): 101-4.
15. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84(3): 1302-13.
16. Gilbert P, Wang M, Wrin T, et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010; 202(4): 595-605.
17. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93.
18. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11(7): 507-15.
19. Duerr A, Huang Y, Buchbinder S, et al. Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). J Infect Dis 2012; 206(2): 258-66.
20. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321(5888): 530-2.
21. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T-cells. Nat Med 2009; 15(8): 876-8.
22. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010; 5(5): 357-61.
23. Koblin BA, Mayer KH, Noonan E, et al. Sexual risk behaviors, circumcision status and pre-existing immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: Step Study. J Acquir Immune Defic Syndr 2012; 60(4): 405-13.
24. Curlin ME, Cassis-Ghavami F, Magaret AS, et al. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. AIDS 2011; 25(2): 153-8.
25. Benlahrech A, Harris J, Meiser A, et al. Adenovirus vector vaccination induces expansion of memory CD4 T-cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009; 106(47): 19940-5.
26. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T-cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T-cells. J Exp Med 2008; 205(12): 2717-25.
27. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15(8): 873-5.
28. Qureshi H, Ma ZM, Huang Y, et al. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J Virol 2012; 86(4): 2239-50.
29. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T-cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T-cells. J Exp Med 2008; 205(12): 2717-25.
30. Perreau M, Welles HC, Pellaton C, et al. The Number of TLR9-Agonist Motifs in the Adenovirus Genome Correlates with Induction of DC Maturation by Adenovirus Immune Complexes. J Virol 2012; 86(11): 6279-85.
31. Michael NL. Rare serotype adenoviral vectors for HIV vaccine development. J Clin Invest 2012; 122(1): 25-7.
32. Lifson JD, Haigwood NL. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. Cold Spring Harb Perspect Med 2012; 2(6): a007310.
33. Reynolds MR, Weiler AM, Piaskowski SM, et al. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 2012; 30(30): 4465-75.
34. Rolland M, Tovanabutra S, Decamp AC, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011; 17(3): 366-71.
35. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011; 6(8): e21225.
36. Kublin JG, Morgan CA, Day TA, et al. HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. Clin Investig (Lond) 2012; 2(3): 245-54.
37. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303(5656): 316.
38. Gilbert PB, Berger JO, Stablein D, et al. Statistical Interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: A Case Study for Statistical Issues in Efficacy Trials. J Infect Dis 2011; 203(7): 969-75.
39. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366(14): 1275-86.
40. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47(3): 401-9.
41. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17(7): 1055-65.
42. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196(9): 1304-12.
43. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54(11): 1615-7.
44. Gilbert P, Self S, Rao M, Naficy A, Clemens J. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. J Clin Epidemiol 2001; 54(1): 68-85.
45. Gilbert PB, McKeague IW, Sun Y. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy. Biostatistics 2008; 9(2): 263-76.
46. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490(7420): 417-20.
47. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73(5): 4009-18.
48. Moore JP. HIV-1 Env antibodies: are we in a bind or going blind? Nat Med 2012; 18(3): 346-7.
49. Burton DR, Hessell AJ, Keele BF, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011; 108(27): 11181-6.
50. Letvin NL, Rao SS, Montefiori DC, et al. Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med 2011; 3(81): 81ra36.
51. Kibler KV, Gomez CE, Perdiguero B, et al. Improved NYVAC-based vaccine vectors. PLoS One 2011; 6(11): e25674.
52. Hope TJ. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat Med 2011; 17(10): 1195-7.
53. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326(5950): 285-9.
54. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329(5993): 856-61.
55. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477(7365): 466-70.
56. Bonsignori M, Montefiori DC, Wu X, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol 2012; 86(8): 4688-92.
57. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329(5993): 856-61.
58. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189(2): 286-91.
59. Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53(2): 450-7.
60. Kalams SA, Parker SD, Elizaga M, et al. Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery. J Infect Dis 2013; 208(5): 818-29.
61. Barouch DH, Kik SV, Weverling GJ, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011; 29(32): 5203-9.
62. Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. J Infect Dis 2011; 203(5): 610-9.
63. Riedmann EM. GeoVax expands its HIV/AIDS vaccine program. Hum Vaccin 2011; 7(6): 596.
64. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106(5): 539-49.
65. Sacha JB, Chung C, Rakasz EG, et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178(5): 2746-54.
66. Cooper D, Wright KJ, Calderon PC, et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces eurovirulence and enhances immunogenicity in mice. J Virol 2008; 82(1): 207-19.
67. Fischer W, Perkins S, Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13(1): 100-6.
68. Santra S, Korber BT, Muldoon M, et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 2008; 105(30): 10489-94.
69. Day T, Morgan C, Kublin JG. Will mosaic vaccine immunogens expand immune response breadth to rival HIV-1 strain diversity? Clin Invest 2013; 3(5): 413-415.
70. Wu Y, Marsh JW. Selective transcription and modulation of resting T-cell activity by preintegrated HIV DNA. Science 2001; 293(5534): 1503-6.
71. Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 2001; 20(7): 1726-38.
72. Lin X, Irwin D, Kanazawa S, et al. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J Virol 2003; 77(15): 8227-36.
73. Altfeld MA, Livingston B, Reshamwala N, et al. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol 2001; 75(3): 1301-11.
74. Ensoli B, Bellino S, Tripiciano A, et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010; 5(11): e13540.
75. Reynolds MR, Weiler AM, Weisgrau KL, et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008; 205(11): 2537-50.
76. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267(5205): 1820-5.
77. Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5(2): 194-203.
78. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 2000; 284(17): 2193-202.
79. Kulkosky J, Bray S. HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication. Curr HIV Res 2006; 4(2): 199-208.
80. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117(10): 2791-9.
81. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24(10): 1598-601.
82. Vanham G, Van GE. Can immunotherapy be useful as a functional cure for infection with Human Immunodeficiency Virus-1? Retrovirology 2012; 9(1): 72.
83. Rolland M, Gilbert P. Evaluating Immune Correlates in HIV Type 1 Vaccine Efficacy Trials: What RV144 May Provide. AIDS Res Hum Retroviruses 2012; 28(4): 400-4.
84. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics 2006; 62(4): 1161-9.
85. Corey L, Nabel GJ, Dieffenbach C, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011; 3(79): 79ps13.
86. Gilbert PB, Grove D, Gabriel E, et al. A sequential phase 2b trial design for evaluation vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Stat Commun Infect Dis 2011; 3(1). pii: 1037.
87. Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 2011; 29(25): 4285-92.
88. Pitisuttithum P, Choopanya K, Rerk-Ngnam S. HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine 2010; 28 Suppl 2: B45-B49.
89. Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM. In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities. AIDS Res Hum Retroviruses 2013; 29(11): 1513-23.
90. Andrasik MP, Karuna ST, Nebergall M, Koblin BA, Kublin JG. Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: A qualitative study exploring HVTN staff perspectives. Vaccine 2013; 31(40): 4398-405.
91. Koblin BA, Andrasik M, Austin J. Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions. J Acquir Immune Defic Syndr 2013; 63 Suppl 2: S183-S186.
92. Lau CY, Swann EM, Singh S, Kafaar Z, Meissner HI, Stansbury JP. Conceptual framework for behavioral and social science in HIV vaccine clinical research. Vaccine 2011; 29(44): 7794-800.
93. Koblin BA, Mayer KH, Noonan E, et al. Sexual Risk Behaviors, Circumcision Status, and Preexisting Immunity to Adenovirus Type 5 Among Men Who Have Sex With Men Participating in a Randomized HIV-1 Vaccine Efficacy Trial: Step Study. J Acquir Immune Defic Syndr 2012; 60(4): 405-13.
94. Andrasik MP, Yoon R, Mooney J, et al. Exploring Barriers and Facilitators to Participation of Male-to-Female Transgender Persons in Preventive HIV Vaccine Clinical Trials. Prev Sci 2013 [Epub ahead of print].